Literature DB >> 30267664

Comparison of gene expression and flow cytometry for immune profiling in chronic lymphocytic leukaemia.

Chia Sharpe1, Joanne Davis2, Kylie Mason3, Constantine Tam4, David Ritchie3, Rachel Koldej2.   

Abstract

Understanding how cancer and cancer therapies affect the immune system is integral to the rational application of immunotherapies. Flow cytometry is the gold standard method of peripheral blood immune cell profiling. However, the requirement for viable cells can limit its applicability, especially in studies of retrospective clinical cohorts. We aimed to determine if gene expression, analysed using the NanoString platform, could be used to quantify the immune populations present in cryopreserved peripheral blood mononuclear cell (PBMC) samples from patients with chronic lymphocytic leukaemia. Cell abundance scores derived from gene expression analysis were significantly correlated with the population frequency quantified by flow cytometry for all subsets analysed, including T cells, NK cells and Monocytes. This study demonstrates that gene expression analysis can be applied to cryopreserved PBMC and provides a concordant and complementary understanding of the immune profile to flow cytometry.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30267664     DOI: 10.1016/j.jim.2018.09.013

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  2 in total

1.  A Digital Microfluidic Device Integrated with Electrochemical Impedance Spectroscopy for Cell-Based Immunoassay.

Authors:  Yuqian Zhang; Yuguang Liu
Journal:  Biosensors (Basel)       Date:  2022-05-12

2.  RNA from stabilized whole blood enables more comprehensive immune gene expression profiling compared to RNA from peripheral blood mononuclear cells.

Authors:  Fleur van der Sijde; Yunlei Li; Rick Schraauwen; Willem de Koning; Casper H J van Eijck; Dana A M Mustafa
Journal:  PLoS One       Date:  2020-06-26       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.